-transparent.png){kind=logo}
Doxorubicin, whose dose-limiting toxicity is cardiomyopathy, was given to four cancer patients. Endomyocardial biopsy specimens and test results of cardiac function were obtained before, during, and after treatment. The biopsy specimens were examined by light and electron microscopy and were graded blindly. Evidence of specific doxorubicin injury was found in 3/4 patients with as little as 180 mg/sq m of the drug and became progressively more severe with higher doses. All test results of cardiac function, including systolic time intervals, remained normal. These data suggest that a specific, progressive subclinical injury to the heart occurs with doxorubicin therapy, which cannot be reliably detected by routine tests. This potential risk must be taken into account with the use of doxorubicin, especially when combined with synergistic agents.
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
January 1979,
Cancer chemotherapy and pharmacology,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
June 1978,
Lancet (London, England),
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
June 1978,
Cancer treatment reports,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
January 1982,
Acta cardiologica,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
August 1988,
Nihon Gan Chiryo Gakkai shi,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
April 1979,
European journal of pediatrics,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
July 1986,
Cancer research,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
January 1978,
Circulation,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
December 1986,
Ugeskrift for laeger,
M A Friedman, and
M J Bozdech, and
M E Billingham, and
A K Rider
December 1990,
European heart journal,
